AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

Exclusion Criteria

• •Amyloidosis, plasma cell leukemia, Waldenstrom Macroglobulinemia, Polyneuropathy Organomegaly Endocrinopathy M-protein and Skin Syndrome, or Smoldering Multiple Myeloma (compliant with WHO criteria);
• •Participants exhibiting clinical signs of central nervous system involvement of MM;
• •Participants with known COPD, or previous history of ILD/pneumonitis;
• •Participants with known moderate or severe persistent asthma within the past 5 years, or uncontrolled asthma of any classification;
• •Participants who have severe cardiovascular disease which is not adequately controlled;
• •Participants who have a history of immunodeficiency disease;
• •Participants with peripheral neuropathy ≥ Grade 2;
• •Primary refractory MM;
• •Participants who have previously received anti-GPRC5D or MMAE-containing treatment;
• •Participants who have previously received allogenic stem cell transplant, or participant has received autologous stem cell transplant within 3 months before the first dose of study intervention;
• •Participants with a history of prior malignancy other than MM within 3 years prior to first dose of study intervention. some exceptions apply;
• •Participants with previous history of active JC virus infection resulting in PML;
• •Participants with a known hypersensitivity to AZD0305 or any of the excipients of the product or to any of the drugs included in the respective modules or who experienced Grade 3 or higher hypersensitivity to prior monoclonal antibody therapy;
• •Participants who have uncontrolled severe illness including but not limited to ongoing active infection requiring therapeutic antibiotics and/or other administration